Identifying individual T cell receptors of optimal avidity for tumor antigens

Frontiers in Immunology

Volumn 6, Issue NOV, 2015, Pages

  Hebeisen, Michael ^a   Allard, Mathilde ^a   Gannon, Philippe O ^a   Schmidt, Julien ^b,c   Speiser, Daniel E ^a,b   Rufer, Nathalie ^a,b  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

^c TCMetrix   (Switzerland)

Author keywords

Cytotoxic T cells; Immunotherapy; Melanoma; NTAmers; T cell functionality; TCR affinity; TCR structural avidity; Tumor antigens

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; HLA A1 ANTIGEN; HLA A2 ANTIGEN; INTERLEUKIN 2; IPILIMUMAB; NIVOLUMAB; PEMBROLIZUMAB; T LYMPHOCYTE RECEPTOR; TUMOR ANTIGEN;

ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; AUTOIMMUNITY; BINDING AFFINITY; BINDING KINETICS; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CELL ENGINEERING; CELL PROLIFERATION; CELLULAR IMMUNITY; CLINICAL EFFECTIVENESS; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; HUMAN; IMMUNE RESPONSE; MAJOR HISTOCOMPATIBILITY COMPLEX; MELANOMA; NEOPLASM; NONHUMAN; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL (TOPIC); REVIEW; SURFACE PLASMON RESONANCE; T LYMPHOCYTE ACTIVATION; TUMOR DIFFERENTIATION; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT;

EID: 84949544712     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2015.00582     Document Type: Review

References (177)

1. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med (2012) 366:2455-65. doi: 10.1056/NEJMoa1200694.
2. Robert C, Thomas L, Bondarenko I, O'Day S, Weber J, Garbe C, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med (2011) 364:2517-26. doi:10.1056/NEJMoa1104621.
3. Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ, et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res (2011) 17:4550-7. doi:10.1158/1078-0432.CCR-11-0116.
4. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 366:2443-54. doi:10.1056/NEJMoa1200690.
5. Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med (2015) 372:2018-28. doi:10.1056/NEJMoa1501824.
6. Couzin-Frankel J. Breakthrough of the year 2013. Cancer immunotherapy. Science (2013) 342:1432-3. doi:10.1126/science.
7. Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol (1999) 17:2105-16.
8. Campoli M, Ferris R, Ferrone S, Wang X. Immunotherapy of malignant disease with tumor antigen-specific monoclonal antibodies. Clin Cancer Res (2010) 16:11-20. doi:10.1158/1078-0432.CCR-09-2345.
9. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 363:711-23. doi:10.1056/NEJMoa1003466.
10. Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann K, McDermott D, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med (2015) 372:2006-17. doi:10.1056/NEJMoa1414428.
11. Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med (2015) 372:2521-32. doi:10.1056/NEJMoa1503093.
12. Fridman WH, Galon J, Pages F, Tartour E, Sautes-Fridman C, Kroemer G. Prognostic and predictive impact of intra-and peritumoral immune infiltrates. Cancer Res (2011) 71:5601-5. doi:10.1158/0008-5472.CAN-11-1316.
13. Mellman I, Coukos G, DranoffG. Cancer immunotherapy comes of age. Nature (2011) 480:480-9. doi:10.1038/nature10673.
14. Pages F, Kirilovsky A, Mlecnik B, Asslaber M, Tosolini M, Bindea G, et al. In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. J Clin Oncol (2009) 27:5944-51. doi:10.1200/JCO.2008.19.6147.
15. Restifo NP, Dudley ME, Rosenberg SA. Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol (2012) 12:269-81. doi:10.1038/nri3191.
16. Besser MJ, Shapira-Frommer R, Itzhaki O, Treves AJ, Zippel DB, Levy D, et al. Adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma: intent-to-treat analysis and efficacy after failure to prior immunotherapies. Clin Cancer Res (2013) 19:4792-800. doi:10.1158/1078-0432.CCR-13-0380.
17. Radvanyi LG, Bernatchez C, Zhang M, Fox PS, Miller P, Chacon J, et al. Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients. Clin Cancer Res (2012) 18:6758-70. doi:10.1158/1078-0432.CCR-12-1177.
18. Rosenberg SA. Cell transfer immunotherapy for metastatic solid cancer-what clinicians need to know. Nat Rev Clin Oncol (2011) 8:577-85. doi:10.1038/nrclinonc.2011.116.
19. Gill S, Porter DL. CAR-modified anti-CD19 T cells for the treatment of B-cell malignancies: rules of the road. Expert Opin Biol Ther (2014) 14:37-49. doi:10.1517/14712598.2014.860442.
20. Dvorak HF. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med (1986) 315:1650-9. doi:10.1056/NEJM198612253152606.
21. Verdeil G, Fuertes Marraco SA, Murray T, Speiser DE. From T cell "exhaustion" to anti-cancer immunity. Biochim Biophys Acta (2015). doi:10.1016/j.bbcan.2015.06.007.
22. Speiser DE, Kyburz D, Stubi U, Hengartner H, Zinkernagel RM. Discrepancy between in vitro measurable and in vivo virus neutralizing cytotoxic T cell reactivities. Low T cell receptor specificity and avidity sufficient for in vitro proliferation or cytotoxicity to peptide-coated target cells but not for in vivo protection. J Immunol (1992) 149:972-80.
23. Alexander-Miller MA, Leggatt GR, Berzofsky JA. Selective expansion of high-or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy. Proc Natl Acad Sci U S A (1996) 93:4102-7. doi:10.1073/pnas.93.9.4102.
24. Foley MH, Forcier T, McAndrew E, Gonzalez M, Chen H, Juelg B, et al. High avidity CD8+ T cells efficiently eliminate motile HIV-infected targets and execute a locally focused program of anti-viral function. PLoS One (2014) 9:e87873. doi:10.1371/journal.pone.0087873.
25. Keane NM, Roberts SG, Almeida CA, Krishnan T, Chopra A, Demaine E, et al. High-avidity, high-IFNgamma-producing CD8 T-cell responses following immune selection during HIV-1 infection. Immunol Cell Biol (2012) 90:224-34. doi:10.1038/icb.2011.34.
26. Dudley ME, Nishimura MI, Holt AK, Rosenberg SA. Antitumor immunization with a minimal peptide epitope (G9-209-2M) leads to a functionally heterogeneous CTL response. J Immunother (1999) 22:288-98. doi:10.1097/00002371-199907000-00002.
27. Dutoit V, Rubio-Godoy V, Dietrich PY, Quiqueres AL, Schnuriger V, Rimoldi D, et al. Heterogeneous T-cell response to MAGE-A10(254-262): high avidity-specific cytolytic T lymphocytes show superior antitumor activity. Cancer Res (2001) 61:5850-6.
28. Zeh HJ III, Perry-Lalley D, Dudley ME, Rosenberg SA, Yang JC. High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy. J Immunol (1999) 162:989-94.
29. Zehn D, Lee SY, Bevan MJ. Complete but curtailed T-cell response to very low-affinity antigen. Nature (2009) 458:211-4. doi:10.1038/nature07657.
30. Gallimore A, Dumrese T, Hengartner H, Zinkernagel RM, Rammensee HG. Protective immunity does not correlate with the hierarchy of virus-specific cytotoxic T cell responses to naturally processed peptides. J Exp Med (1998) 187:1647-57. doi:10.1084/jem.187.10.1647-b.
31. Rosenberg SA, Dudley ME, Restifo NP. Cancer immunotherapy. N Engl J Med (2008) 359:1072. doi:10.1056/NEJMc081511.
32. Engels B, Engelhard VH, Sidney J, Sette A, Binder DC, Liu RB, et al. Relapse or eradication of cancer is predicted by peptide-major histocompatibility complex affinity. Cancer Cell (2013) 23:516-26. doi:10.1016/j.ccr.2013.03.018.
33. Besser MJ, Shapira-Frommer R, Treves AJ, Zippel D, Itzhaki O, Schallmach E, et al. Minimally cultured or selected autologous tumor-infiltrating lymphocytes after a lympho-depleting chemotherapy regimen in metastatic melanoma patients. J Immunother (2009) 32:415-23. doi:10.1097/CJI.0b013e31819c8bda.
34. Dudley ME, Yang JC, Sherry R, Hughes MS, Royal R, Kammula U, et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol (2008) 26:5233-9. doi:10.1200/JCO.2008.16.5449.
35. KlebanoffCA, Gattinoni L, Palmer DC, Muranski P, Ji Y, Hinrichs CS, et al. Determinants of successful CD8+ T-cell adoptive immunotherapy for large established tumors in mice. Clin Cancer Res (2011) 17:5343-52. doi:10.1158/1078-0432.CCR-11-0503.
36. Schwartzentruber DJ, Hom SS, Dadmarz R, White DE, Yannelli JR, Steinberg SM, et al. In vitro predictors of therapeutic response in melanoma patients receiving tumor-infiltrating lymphocytes and interleukin-2. J Clin Oncol (1994) 12:1475-83.
37. Zehn D, King C, Bevan MJ, Palmer E. TCR signaling requirements for activating T cells and for generating memory. Cell Mol Life Sci (2012) 69:1565-75. doi:10.1007/s00018-012-0965-x.
38. Corse E, Gottschalk RA, Allison JP. Strength of TCR-peptide/MHC interactions and in vivo T cell responses. J Immunol (2011) 186:5039-45. doi:10.4049/jimmunol.1003650.
39. Vigano S, Utzschneider DT, Perreau M, Pantaleo G, Zehn D, Harari A. Functional avidity: a measure to predict the efficacy of effector T cells? Clin Dev Immunol (2012) 2012:153863. doi:10.1155/2012/153863.
40. Stone JD, Chervin AS, Kranz DM. T-cell receptor binding affinities and kinetics: impact on T-cell activity and specificity. Immunology (2009) 126:165-76. doi:10.1111/j.1365-2567.2008.03015.x.
41. Gannon PO, Wieckowski S, Baumgaertner P, Hebeisen M, Allard M, Speiser DE, et al. Quantitative TCR:pMHC dissociation rate assessment by NTAmers reveals antimelanoma T cell repertoires enriched for high functional competence. J Immunol (2015) 195(1):356-66. doi:10.4049/jimmunol.1403145.
42. Hebeisen M, Schmidt J, Guillaume P, Baumgaertner P, Speiser DE, Luescher I, et al. Identification of rare high-avidity, tumor-reactive CD8+ T cells by monomeric TCR-ligand off-rates measurements on living cells. Cancer Res (2015) 75:1983-91. doi:10.1158/0008-5472.CAN-14-3516.
43. Aleksic M, Liddy N, Molloy PE, Pumphrey N, Vuidepot A, Chang KM, et al. Different affinity windows for virus and cancer-specific T-cell receptors: implications for therapeutic strategies. Eur J Immunol (2012) 42:3174-9. doi:10.1002/eji.201242606.
44. Klein L, Kyewski B, Allen PM, Hogquist KA. Positive and negative selection of the T cell repertoire: what thymocytes see (and don't see). Nat Rev Immunol (2014) 14:377-91. doi:10.1038/nri3667.
45. Palmer E, Naeher D. Affinity threshold for thymic selection through a T-cell receptor-co-receptor zipper. Nat Rev Immunol (2009) 9:207-13. doi:10.1038/nri2469.
46. Davis MM, Boniface JJ, Reich Z, Lyons D, Hampl J, Arden B, et al. Ligand recognition by alpha beta T cell receptors. Annu Rev Immunol (1998) 16:523-44. doi:10.1146/annurev.immunol.16.1.523.
47. Boon T, Coulie PG, Van den Eynde BJ, van der Bruggen P. Human T cell responses against melanoma. Annu Rev Immunol (2006) 24:175-208. doi:10.1146/annurev.immunol.24.021605.090733.
48. Romero P, Valmori D, Pittet MJ, Zippelius A, Rimoldi D, Levy F, et al. Antigenicity and immunogenicity of Melan-A/MART-1 derived peptides as targets for tumor reactive CTL in human melanoma. Immunol Rev (2002) 188:81-96. doi:10.1034/j.1600-065X.2002.18808.x.
49. Kyewski B, Klein L. A central role for central tolerance. Annu Rev Immunol (2006) 24:571-606. doi:10.1146/annurev.immunol.23.021704.115601.
50. Kurts C, Kosaka H, Carbone FR, Miller JF, Heath WR. Class I-restricted cross-presentation of exogenous self-antigens leads to deletion of autoreactive CD8(+) T cells. J Exp Med (1997) 186:239-45. doi:10.1084/jem.186.2.239.
51. McMahan RH, Slansky JE. Mobilizing the low-avidity T cell repertoire to kill tumors. Semin Cancer Biol (2007) 17:317-29. doi:10.1016/j.semcancer.2007.06.006.
52. Turner MJ, Jellison ER, Lingenheld EG, Puddington L, Lefrancois L. Avidity maturation of memory CD8 T cells is limited by self-antigen expression. J Exp Med (2008) 205:1859-68. doi:10.1084/jem.20072390.
53. Zehn D, Bevan MJ. T cells with low avidity for a tissue-restricted antigen routinely evade central and peripheral tolerance and cause autoimmunity. Immunity (2006) 25:261-70. doi:10.1016/j.immuni.2006.06.009.
54. Chlewicki LK, Holler PD, Monti BC, Clutter MR, Kranz DM. High-affinity, peptide-specific T cell receptors can be generated by mutations in CDR1, CDR2 or CDR3. J Mol Biol (2005) 346:223-39. doi:10.1016/j.jmb.2004.11.057.
55. Holler PD, Holman PO, Shusta EV, O'Herrin S, Wittrup KD, Kranz DM. In vitro evolution of a T cell receptor with high affinity for peptide/MHC. Proc Natl Acad Sci U S A (2000) 97:5387-92. doi:10.1073/pnas.080078297.
56. Li Y, Moysey R, Molloy PE, Vuidepot AL, Mahon T, Baston E, et al. Directed evolution of human T-cell receptors with picomolar affinities by phage display. Nat Biotechnol (2005) 23:349-54. doi:10.1038/nbt1070.
57. Dunn SM, Rizkallah PJ, Baston E, Mahon T, Cameron B, Moysey R, et al. Directed evolution of human T cell receptor CDR2 residues by phage display dramatically enhances affinity for cognate peptide-MHC without increasing apparent cross-reactivity. Protein Sci (2006) 15:710-21. doi:10.1110/ps.051936406.
58. Holler PD, Chlewicki LK, Kranz DM. TCRs with high affinity for foreign pMHC show self-reactivity. Nat Immunol (2003) 4:55-62. doi:10.1038/ni863.
59. Robbins PF, Li YF, El-Gamil M, Zhao Y, Wargo JA, Zheng Z, et al. Single and dual amino acid substitutions in TCR CDRs can enhance antigen-specific T cell functions. J Immunol (2008) 180:6116-31. doi:10.4049/jimmunol.180.9.6116.
60. Zhao Y, Bennett AD, Zheng Z, Wang QJ, Robbins PF, Yu LY, et al. High-affinity TCRs generated by phage display provide CD4+ T cells with the ability to recognize and kill tumor cell lines. J Immunol (2007) 179:5845-54. doi:10.4049/jimmunol.179.9.5845.
61. Haidar JN, Pierce B, Yu Y, Tong W, Li M, Weng Z. Structure-based design of a T-cell receptor leads to nearly 100-fold improvement in binding affinity for pepMHC. Proteins (2009) 74:948-60. doi:10.1002/prot.22203.
62. Malecek K, Grigoryan A, Zhong S, Gu WJ, Johnson LA, Rosenberg SA, et al. Specific increase in potency via structure-based design of a TCR. J Immunol (2014) 193:2587-99. doi:10.4049/jimmunol.1302344.
63. Zoete V, Irving MB, Michielin O. MM-GBSA binding free energy decomposition and T cell receptor engineering. J Mol Recognit (2010) 23:142-52. doi:10.1002/jmr.1005.
64. Zoete V, Irving M, Ferber M, Cuendet MA, Michielin O. Structure-based, rational design of T cell receptors. Front Immunol (2013) 4:268. doi:10.3389/fimmu.2013.00268.
65. Irving M, Zoete V, Hebeisen M, Schmid D, Baumgartner P, Guillaume P, et al. Interplay between T cell receptor binding kinetics and the level of cognate peptide presented by major histocompatibility complexes governs CD8+ T cell responsiveness. J Biol Chem (2012) 287:23068-78. doi:10.1074/jbc. M112.357673.
66. Schmid DA, Irving MB, Posevitz V, Hebeisen M, Posevitz-Fejfar A, Sarria JC, et al. Evidence for a TCR affinity threshold delimiting maximal CD8 T cell function. J Immunol (2010) 184:4936-46. doi:10.4049/jimmunol.1000173.
67. Hebeisen M, Baitsch L, Presotto D, Baumgaertner P, Romero P, Michielin O, et al. SHP-1 phosphatase activity counteracts increased T cell receptor affinity. J Clin Invest (2013) 123:1044-56. doi:10.1172/JCI65325.
68. Alam SM, Davies GM, Lin CM, Zal T, Nasholds W, Jameson SC, et al. Qualitative and quantitative differences in T cell receptor binding of agonist and antagonist ligands. Immunity (1999) 10:227-37. doi:10.1016/S1074-7613(00)80023-0.
69. Carreno LJ, Bueno SM, Bull P, Nathenson SG, Kalergis AM. The half-life of the T-cell receptor/peptide-major histocompatibility complex interaction can modulate T-cell activation in response to bacterial challenge. Immunology (2007) 121:227-37. doi:10.1111/j.1365-2567.2007.02561.x.
70. Malherbe L, Hausl C, Teyton L, McHeyzer-Williams MG. Clonal selection of helper T cells is determined by an affinity threshold with no further skewing of TCR binding properties. Immunity (2004) 21:669-79. doi:10.1016/j.immuni.2004.09.008.
71. Rosette C, Werlen G, Daniels MA, Holman PO, Alam SM, Travers PJ, et al. The impact of duration versus extent of TCR occupancy on T cell activation: a revision of the kinetic proofreading model. Immunity (2001) 15:59-70. doi:10.1016/S1074-7613(01)00173-X.
72. Sykulev Y, Joo M, Vturina I, Tsomides TJ, Eisen HN. Evidence that a single peptide-MHC complex on a target cell can elicit a cytolytic T cell response. Immunity (1996) 4:565-71. doi:10.1016/S1074-7613(00)80483-5.
73. Aleksic M, Dushek O, Zhang H, Shenderov E, Chen JL, Cerundolo V, et al. Dependence of T cell antigen recognition on T cell receptor-peptide MHC confinement time. Immunity (2010) 32:163-74. doi:10.1016/j.immuni.2009.11.013.
74. Boulter JM, Schmitz N, Sewell AK, Godkin AJ, Bachmann MF, Gallimore AM. Potent T cell agonism mediated by a very rapid TCR/pMHC interaction. Eur J Immunol (2007) 37:798-806. doi:10.1002/eji.200636743.
75. Carreno LJ, Riquelme EM, Gonzalez PA, Espagnolle N, Riedel CA, Valitutti S, et al. T-cell antagonism by short half-life pMHC ligands can be mediated by an efficient trapping of T-cell polarization toward the APC. Proc Natl Acad Sci U S A (2010) 107:210-5. doi:10.1073/pnas.0911258107.
76. Chen JL, Morgan AJ, Stewart-Jones G, Shepherd D, Bossi G, Wooldridge L, et al. Ca2+ release from the endoplasmic reticulum of NY-ESO-1-specific T cells is modulated by the affinity of TCR and by the use of the CD8 coreceptor. J Immunol (2010) 184:1829-39. doi:10.4049/jimmunol.0902103.
77. Corse E, Gottschalk RA, Krogsgaard M, Allison JP. Attenuated T cell responses to a high-potency ligand in vivo. PLoS Biol (2010) 8:e1000481. doi:10.1371/journal.pbio.1000481.
78. Kalergis AM, Boucheron N, Doucey MA, Palmieri E, Goyarts EC, Vegh Z, et al. Efficient T cell activation requires an optimal dwell-time of interaction between the TCR and the pMHC complex. Nat Immunol (2001) 2:229-34. doi:10.1038/85286.
79. Liu B, Zhong S, Malecek K, Johnson LA, Rosenberg SA, Zhu C, et al. 2D TCR-pMHC-CD8 kinetics determines T-cell responses in a self-antigen-specific TCR system. Eur J Immunol (2014) 44:239-50. doi:10.1002/eji.201343774.
80. Riquelme E, Carreno LJ, Gonzalez PA, Kalergis AM. The duration of TCR/pMHC interactions regulates CTL effector function and tumor-killing capacity. Eur J Immunol (2009) 39:2259-69. doi:10.1002/eji.200939341.
81. Tan MP, Gerry AB, Brewer JE, Melchiori L, Bridgeman JS, Bennett AD, et al. T cell receptor binding affinity governs the functional profile of cancer-specific CD8+ T cells. Clin Exp Immunol (2015) 180:255-70. doi:10.1111/cei.12570.
82. Tian S, Maile R, Collins EJ, Frelinger JA. CD8+ T cell activation is governed by TCR-peptide/MHC affinity, not dissociation rate. J Immunol (2007) 179:2952-60. doi:10.4049/jimmunol.179.5.2952.
83. Zhong S, Malecek K, Johnson LA, Yu Z, Vega-Saenz de Miera E, Darvishian F, et al. T-cell receptor affinity and avidity defines antitumor response and autoimmunity in T-cell immunotherapy. Proc Natl Acad Sci U S A (2013) 110:6973-8. doi:10.1073/pnas.1221609110.
84. McMahan RH, McWilliams JA, Jordan KR, Dow SW, Wilson DB, Slansky JE. Relating TCR-peptide-MHC affinity to immunogenicity for the design of tumor vaccines. J Clin Invest (2006) 116:2543-51.
85. Thomas S, Stauss HJ, Morris EC. Molecular immunology lessons from therapeutic T-cell receptor gene transfer. Immunology (2010) 129:170-7. doi:10.1111/j.1365-2567.2009.03227.x.
86. Gonzalez PA, Carreno LJ, Coombs D, Mora JE, Palmieri E, Goldstein B, et al. T cell receptor binding kinetics required for T cell activation depend on the density of cognate ligand on the antigen-presenting cell. Proc Natl Acad Sci U S A (2005) 102:4824-9. doi:10.1073/pnas.0500922102.
87. Holler PD, Kranz DM. Quantitative analysis of the contribution of TCR/pepMHC affinity and CD8 to T cell activation. Immunity (2003) 18:255-64. doi:10.1016/S1074-7613(03)00019-0.
88. Chervin AS, Stone JD, Soto CM, Engels B, Schreiber H, Roy EJ, et al. Design of T-cell receptor libraries with diverse binding properties to examine adoptive T-cell responses. Gene Ther (2013) 20:634-44. doi:10.1038/gt.2012.80.
89. Engels B, Chervin AS, Sant AJ, Kranz DM, Schreiber H. Long-term persistence of CD4(+) but rapid disappearance of CD8(+) T cells expressing an MHC class I-restricted TCR of nanomolar affinity. Mol Ther (2012) 20:652-60. doi:10.1038/mt.2011.286.
90. Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science (2006) 314:126-9. doi:10.1126/science.1129003.
91. Borbulevych OY, Santhanagopolan SM, Hossain M, Baker BM. TCRs used in cancer gene therapy cross-react with MART-1/Melan-A tumor antigens via distinct mechanisms. J Immunol (2011) 187:2453-63. doi:10.4049/jimmunol.1101268.
92. Johnson LA, Morgan RA, Dudley ME, Cassard L, Yang JC, Hughes MS, et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood (2009) 114:535-46. doi:10.1182/blood-2009-03-211714.
93. Robbins PF, Morgan RA, Feldman SA, Yang JC, Sherry RM, Dudley ME, et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol (2011) 29:917-24. doi:10.1200/JCO.2010.32.2537.
94. Overwijk WW, Theoret MR, Finkelstein SE, Surman DR, de Jong LA, Vyth-Dreese FA, et al. Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J Exp Med (2003) 198:569-80. doi:10.1084/jem.20030590.
95. Yee C, Thompson JA, Roche P, Byrd DR, Lee PP, Piepkorn M, et al. Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of t cell-mediated vitiligo. J Exp Med (2000) 192:1637-44. doi:10.1084/jem.192.11.1637.
96. Yeh S, Karne NK, Kerkar SP, Heller CK, Palmer DC, Johnson LA, et al. Ocular and systemic autoimmunity after successful tumor-infiltrating lymphocyte immunotherapy for recurrent, metastatic melanoma. Ophthalmology (2009) 116(981-989):e981. doi:10.1016/j.ophtha.2008.12.004.
97. Schmitt TM, Aggen DH, Stromnes IM, Dossett ML, Richman SA, Kranz DM, et al. Enhanced-affinity murine T-cell receptors for tumor/self-antigens can be safe in gene therapy despite surpassing the threshold for thymic selection. Blood (2013) 122:348-56. doi:10.1182/blood-2013-01-478164.
98. Palmer DC, Chan CC, Gattinoni L, Wrzesinski C, Paulos CM, Hinrichs CS, et al. Effective tumor treatment targeting a melanoma/melanocyte-associated antigen triggers severe ocular autoimmunity. Proc Natl Acad Sci U S A (2008) 105:8061-6. doi:10.1073/pnas.0710929105.
99. Kunert A, Straetemans T, Govers C, Lamers C, Mathijssen R, Sleijfer S, et al. TCR-engineered T cells meet new challenges to treat solid tumors: choice of antigen, T cell fitness, and sensitization of tumor milieu. Front Immunol (2013) 4:363. doi:10.3389/fimmu.2013.00363.
100. Robbins PF, Lu YC, El-Gamil M, Li YF, Gross C, Gartner J, et al. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med (2013) 19:747-52. doi:10.1038/nm.3161.
101. Coulie PG, Lehmann F, Lethe B, Herman J, Lurquin C, Andrawiss M, et al. A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma. Proc Natl Acad Sci U S A (1995) 92:7976-80. doi:10.1073/pnas.92.17.7976.
102. Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science (2015) 348:69-74. doi:10.1126/science.aaa4971.
103. Stone JD, Harris DT, Kranz DM. TCR affinity for p/MHC formed by tumor antigens that are self-proteins: impact on efficacy and toxicity. Curr Opin Immunol (2015) 33:16-22. doi:10.1016/j.coi.2015.01.003.
104. Cameron BJ, Gerry AB, Dukes J, Harper JV, Kannan V, Bianchi FC, et al. Identification of a titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells. Sci Transl Med (2013) 5:197ra103. doi:10.1126/scitranslmed.3006034.
105. Linette GP, Stadtmauer EA, Maus MV, Rapoport AP, Levine BL, Emery L, et al. Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood (2013) 122:863-71. doi:10.1182/blood-2013-03-490565.
106. Morgan RA, Chinnasamy N, Abate-Daga D, Gros A, Robbins PF, Zheng Z, et al. Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J Immunother (2013) 36:133-51. doi:10.1097/CJI.0b013e3182829903.
107. June CH, Maus MV, Plesa G, Johnson LA, Zhao Y, Levine BL, et al. Engineered T cells for cancer therapy. Cancer Immunol Immunother (2014) 63:969-75. doi:10.1007/s00262-014-1568-1.
108. Hebeisen M, Oberle SG, Presotto D, Speiser DE, Zehn D, Rufer N. Molecular insights for optimizing T cell receptor specificity against cancer. Front Immunol (2013) 4:154. doi:10.3389/fimmu.2013.00154.
109. Slansky JE, Jordan KR. The Goldilocks model for TCR-too much attraction might not be best for vaccine design. PLoS Biol (2010) 8:e1000482. doi:10.1371/journal.pbio.1000482.
110. Fivash M, Towler EM, Fisher RJ. BIAcore for macromolecular interaction. Curr Opin Biotechnol (1998) 9:97-101. doi:10.1016/S0958-1669(98)80091-8.
111. Bridgeman JS, Sewell AK, Miles JJ, Price DA, Cole DK. Structural and biophysical determinants of alphabeta T-cell antigen recognition. Immunology (2012) 135:9-18. doi:10.1111/j.1365-2567.2011.03515.x.
112. Corr M, Slanetz AE, Boyd LF, Jelonek MT, Khilko S, al-Ramadi BK, et al. T cell receptor-MHC class I peptide interactions: affinity, kinetics, and specificity. Science (1994) 265:946-9. doi:10.1126/science.8052850.
113. Edwards LJ, Zarnitsyna VI, Hood JD, Evavold BD, Zhu C. Insights into T cell recognition of antigen: significance of two-dimensional kinetic parameters. Front Immunol (2012) 3:86. doi:10.3389/fimmu.2012.00086.
114. Huang J, Zarnitsyna VI, Liu B, Edwards LJ, Jiang N, Evavold BD, et al. The kinetics of two-dimensional TCR and pMHC interactions determine T-cell responsiveness. Nature (2010) 464:932-6. doi:10.1038/nature08944.
115. Huppa JB, Axmann M, Mortelmaier MA, Lillemeier BF, Newell EW, Brameshuber M, et al. TCR-peptide-MHC interactions in situ show accelerated kinetics and increased affinity. Nature (2010) 463:963-7. doi:10.1038/nature08746.
116. Pryshchep S, Zarnitsyna VI, Hong J, Evavold BD, Zhu C. Accumulation of serial forces on TCR and CD8 frequently applied by agonist antigenic peptides embedded in MHC molecules triggers calcium in T cells. J Immunol (2014) 193:68-76. doi:10.4049/jimmunol.1303436.
117. Hong J, Persaud SP, Horvath S, Allen PM, Evavold BD, Zhu C. Force-regulated in situ TCR-peptide-bound MHC class II kinetics determine functions of CD4+ T cells. J Immunol (2015) 195:3557-64. doi:10.4049/jimmunol.1501407.
118. Casas J, Brzostek J, Zarnitsyna VI, Hong JS, Wei Q, Hoerter JA, et al. Ligand-engaged TCR is triggered by Lck not associated with CD8 coreceptor. Nat Commun (2014) 5:5624. doi:10.1038/ncomms6624.
119. Jiang N, Huang J, Edwards LJ, Liu B, Zhang Y, Beal CD, et al. Two-stage cooperative T cell receptor-peptide major histocompatibility complex-CD8 trimolecular interactions amplify antigen discrimination. Immunity (2011) 34:13-23. doi:10.1016/j.immuni.2010.12.017.
120. Chen W, Zhu C. Mechanical regulation of T-cell functions. Immunol Rev (2013) 256:160-76. doi:10.1111/imr.12122.
121. Dushek O, van der Merwe PA. An induced rebinding model of antigen discrimination. Trends Immunol (2014) 35:153-8. doi:10.1016/j.it.2014.02.002.
122. Schmidt J, Dojcinovic D, Guillaume P, Luescher I. Analysis, isolation, and activation of antigen-specific CD4(+) and CD8(+) T cells by soluble MHC-peptide complexes. Front Immunol (2013) 4:218. doi:10.3389/fimmu.2013.00218.
123. Zhu C, Jiang N, Huang J, Zarnitsyna VI, Evavold BD. Insights from in situ analysis of TCR-pMHC recognition: response of an interaction network. Immunol Rev (2013) 251:49-64. doi:10.1111/imr.12016.
124. Angelov GS, Guillaume P, Cebecauer M, Bosshard G, Dojcinovic D, Baumgaertner P, et al. Soluble MHC-peptide complexes containing long rigid linkers abolish CTL-mediated cytotoxicity. J Immunol (2006) 176:3356-65. doi:10.4049/jimmunol.176.6.3356.
125. Cebecauer M, Guillaume P, Mark S, Michielin O, Boucheron N, Bezard M, et al. CD8+ cytotoxic T lymphocyte activation by soluble major histocompatibility complex-peptide dimers. J Biol Chem (2005) 280:23820-8. doi:10.1074/jbc. M500654200.
126. Dolton G, Lissina A, Skowera A, Ladell K, Tungatt K, Jones E, et al. Comparison of peptide-major histocompatibility complex tetramers and dextramers for the identification of antigen-specific T cells. Clin Exp Immunol (2014) 177:47-63. doi:10.1111/cei.12339.
127. Kronig H, Hofer K, Conrad H, Guilaume P, Muller J, Schiemann M, et al. Allorestricted T lymphocytes with a high avidity T-cell receptor towards NY-ESO-1 have potent anti-tumor activity. Int J Cancer (2009) 125:649-55. doi:10.1002/ijc.24414.
128. Yee C, Savage PA, Lee PP, Davis MM, Greenberg PD. Isolation of high avidity melanoma-reactive CTL from heterogeneous populations using peptide-MHC tetramers. J Immunol (1999) 162:2227-34.
129. Bullock TN, Mullins DW, Colella TA, Engelhard VH. Manipulation of avidity to improve effectiveness of adoptively transferred CD8(+) T cells for melanoma immunotherapy in human MHC class I-transgenic mice. J Immunol (2001) 167:5824-31. doi:10.4049/jimmunol.167.10.5824.
130. Hombrink P, Raz Y, Kester MG, de Boer R, Weissbrich B, von dem Borne PA, et al. Mixed functional characteristics correlating with TCR-ligand koff-rate of MHC-tetramer reactive T cells within the naive T-cell repertoire. Eur J Immunol (2013) 43:3038-50. doi:10.1002/eji.201343397.
131. Wilde S, Sommermeyer D, Leisegang M, Frankenberger B, Mosetter B, Uckert W, et al. Human antitumor CD8+ T cells producing Th1 polycytokines show superior antigen sensitivity and tumor recognition. J Immunol (2012) 189:598-605. doi:10.4049/jimmunol.1102165.
132. Dutoit V, Rubio-Godoy V, Doucey MA, Batard P, Lienard D, Rimoldi D, et al. Functional avidity of tumor antigen-specific CTL recognition directly correlates with the stability of MHC/peptide multimer binding to TCR. J Immunol (2002) 168:1167-71. doi:10.4049/jimmunol.168.3.1167.
133. Laugel B, van den Berg HA, Gostick E, Cole DK, Wooldridge L, Boulter J, et al. Different T cell receptor affinity thresholds and CD8 coreceptor dependence govern cytotoxic T lymphocyte activation and tetramer binding properties. J Biol Chem (2007) 282:23799-810. doi:10.1074/jbc. M700976200.
134. Wang XL, Altman JD. Caveats in the design of MHC class I tetramer/antigen-specific T lymphocytes dissociation assays. J Immunol Methods (2003) 280:25-35. doi:10.1016/S0022-1759(03)00079-6.
135. Knabel M, Franz TJ, Schiemann M, Wulf A, Villmow B, Schmidt B, et al. Reversible MHC multimer staining for functional isolation of T-cell populations and effective adoptive transfer. Nat Med (2002) 8:631-7. doi:10.1038/nm0602-631.
136. Neudorfer J, Schmidt B, Huster KM, Anderl F, Schiemann M, Holzapfel G, et al. Reversible HLA multimers (Streptamers) for the isolation of human cytotoxic T lymphocytes functionally active against tumor-and virus-derived antigens. J Immunol Methods (2007) 320:119-31. doi:10.1016/j.jim.2007.01.001.
137. Guillaume P, Baumgaertner P, Angelov GS, Speiser D, Luescher IF. Fluorescence-activated cell sorting and cloning of bona fide CD8+ CTL with reversible MHC-peptide and antibody Fab' conjugates. J Immunol (2006) 177:3903-12. doi:10.4049/jimmunol.177.6.3903.
138. Schmidt J, Guillaume P, Irving M, Baumgaertner P, Speiser D, Luescher IF. Reversible major histocompatibility complex I-peptide multimers containing Ni(2+)-nitrilotriacetic acid peptides and histidine tags improve analysis and sorting of CD8(+) T cells. J Biol Chem (2011) 286:41723-35. doi:10.1074/jbc. M111.283127.
139. Nauerth M, Weissbrich B, Knall R, Franz T, Dossinger G, Bet J, et al. TCR-ligand koffrate correlates with the protective capacity of antigen-specific CD8+ T cells for adoptive transfer. Sci Transl Med (2013) 5:192ra187. doi:10.1126/scitranslmed.3005958.
140. Nauerth M, Weissbrich B, Busch DH. The clinical potential for koff-rate measurement in adoptive immunotherapy. Expert Rev Clin Immunol (2013) 9:1151-3. doi:10.1586/1744666X.2013.855609.
141. Artyomov MN, Lis M, Devadas S, Davis MM, Chakraborty AK. CD4 and CD8 binding to MHC molecules primarily acts to enhance Lck delivery. Proc Natl Acad Sci U S A (2010) 107:16916-21. doi:10.1073/pnas.1010568107.
142. Salter RD, Benjamin RJ, Wesley PK, Buxton SE, Garrett TP, Clayberger C, et al. A binding site for the T-cell co-receptor CD8 on the alpha 3 domain of HLA-A2. Nature (1990) 345:41-6. doi:10.1038/345041a0.
143. Wooldridge L, van den Berg HA, Glick M, Gostick E, Laugel B, Hutchinson SL, et al. Interaction between the CD8 coreceptor and major histocompatibility complex class I stabilizes T cell receptor-antigen complexes at the cell surface. J Biol Chem (2005) 280:27491-501. doi:10.1074/jbc. M500555200.
144. Cole DK, Laugel B, Clement M, Price DA, Wooldridge L, Sewell AK. The molecular determinants of CD8 co-receptor function. Immunology (2012) 137:139-48. doi:10.1111/j.1365-2567.2012.03625.x.
145. Kersh GJ, Kersh EN, Fremont DH, Allen PM. High-and low-potency ligands with similar affinities for the TCR: the importance of kinetics in TCR signaling. Immunity (1998) 9:817-26. doi:10.1016/S1074-7613(00)80647-0.
146. Krogsgaard M, Davis MM. How T cells 'see' antigen. Nat Immunol (2005) 6:239-45. doi:10.1038/ni1173.
147. Matsui K, Boniface JJ, Steffner P, Reay PA, Davis MM. Kinetics of T-cell receptor binding to peptide/I-Ek complexes: correlation of the dissociation rate with T-cell responsiveness. Proc Natl Acad Sci U S A (1994) 91:12862-6. doi:10.1073/pnas.91.26.12862.
148. McKeithan TW. Kinetic proofreading in T-cell receptor signal transduction. Proc Natl Acad Sci U S A (1995) 92:5042-6. doi:10.1073/pnas.92.11.5042.
149. Valitutti S, Muller S, Cella M, Padovan E, Lanzavecchia A. Serial triggering of many T-cell receptors by a few peptide-MHC complexes. Nature (1995) 375:148-51. doi:10.1038/375148a0.
150. Govern CC, Paczosa MK, Chakraborty AK, Huseby ES. Fast on-rates allow short dwell time ligands to activate T cells. Proc Natl Acad Sci U S A (2010) 107:8724-9. doi:10.1073/pnas.1000966107.
151. Lovgren T, Baumgaertner P, Wieckowski S, Devevre E, Guillaume P, Luescher I, et al. Enhanced cytotoxicity and decreased CD8 dependence of human cancer-specific cytotoxic T lymphocytes after vaccination with low peptide dose. Cancer Immunol Immunother (2012) 61:817-26. doi:10.1007/s00262-011-1140-1.
152. Speiser DE, Wieckowski S, Gupta B, Iancu EM, Baumgaertner P, Baitsch L, et al. Single cell analysis reveals similar functional competence of dominant and nondominant CD8 T-cell clonotypes. Proc Natl Acad Sci U S A (2011) 108:15318-23. doi:10.1073/pnas.1105419108.
153. Au-Yeung BB, Zikherman J, Mueller JL, Ashouri JF, Matloubian M, Cheng DA, et al. A sharp T-cell antigen receptor signaling threshold for T-cell proliferation. Proc Natl Acad Sci U S A (2014) 111:E3679-88. doi:10.1073/pnas.1413726111.
154. Bachmann MF, Sebzda E, Kundig TM, Shahinian A, Speiser DE, Mak TW, et al. T cell responses are governed by avidity and co-stimulatory thresholds. Eur J Immunol (1996) 26:2017-22. doi:10.1002/eji.1830260908.
155. Faroudi M, Utzny C, Salio M, Cerundolo V, Guiraud M, Muller S, et al. Lytic versus stimulatory synapse in cytotoxic T lymphocyte/target cell interaction: manifestation of a dual activation threshold. Proc Natl Acad Sci U S A (2003) 100:14145-50. doi:10.1073/pnas.2334336100.
156. Fonteneau JF, Le Drean E, Le Guiner S, Gervois N, Diez E, Jotereau F. Heterogeneity of biologic responses of melanoma-specific CTL. J Immunol (1997) 159:2831-9.
157. Guy CS, Vignali KM, Temirov J, Bettini ML, Overacre AE, Smeltzer M, et al. Distinct TCR signaling pathways drive proliferation and cytokine production in T cells. Nat Immunol (2013) 14:262-70. doi:10.1038/ni.2538.
158. Valitutti S, Muller S, Dessing M, Lanzavecchia A. Different responses are elicited in cytotoxic T lymphocytes by different levels of T cell receptor occupancy. J Exp Med (1996) 183:1917-21. doi:10.1084/jem.183.4.1917.
159. Wiedemann A, Depoil D, Faroudi M, Valitutti S. Cytotoxic T lymphocytes kill multiple targets simultaneously via spatiotemporal uncoupling of lytic and stimulatory synapses. Proc Natl Acad Sci U S A (2006) 103:10985-90. doi:10.1073/pnas.0600651103.
160. La Gruta NL, Doherty PC, Turner SJ. A correlation between function and selected measures of T cell avidity in influenza virus-specific CD8+ T cell responses. Eur J Immunol (2006) 36:2951-9. doi:10.1002/eji.200636390.
161. Busch DH, Pamer EG. T cell affinity maturation by selective expansion during infection. J Exp Med (1999) 189:701-10. doi:10.1084/jem.189.4.701.
162. Cukalac T, Chadderton J, Handel A, Doherty PC, Turner SJ, Thomas PG, et al. Reproducible selection of high avidity CD8+ T-cell clones following secondary acute virus infection. Proc Natl Acad Sci U S A (2014) 111:1485-90. doi:10.1073/pnas.1323736111.
163. Dzutsev AH, Belyakov IM, Isakov DV, Margulies DH, Berzofsky JA. Avidity of CD8 T cells sharpens immunodominance. Int Immunol (2007) 19:497-507. doi:10.1093/intimm/dxm016.
164. Liu J, Cao S, Peppers G, Kim SH, Graham BS. Clonotype-specific avidity influences the dynamics and hierarchy of virus-specific regulatory and effector CD4(+) T-cell responses. Eur J Immunol (2014) 44:1058-68. doi:10.1002/eji.201343766.
165. Savage PA, Boniface JJ, Davis MM. A kinetic basis for T cell receptor repertoire selection during an immune response. Immunity (1999) 10:485-92. doi:10.1016/S1074-7613(00)80048-5.
166. Price DA, Brenchley JM, RuffLE, Betts MR, Hill BJ, Roederer M, et al. Avidity for antigen shapes clonal dominance in CD8+ T cell populations specific for persistent DNA viruses. J Exp Med (2005) 202:1349-61. doi:10.1084/jem.20051357.
167. Trautmann L, Rimbert M, Echasserieau K, Saulquin X, Neveu B, Dechanet J, et al. Selection of T cell clones expressing high-affinity public TCRs within human cytomegalovirus-specific CD8 T cell responses. J Immunol (2005) 175:6123-32. doi:10.4049/jimmunol.175.9.6123.
168. Derby M, Alexander-Miller M, Tse R, Berzofsky J. High-avidity CTL exploit two complementary mechanisms to provide better protection against viral infection than low-avidity CTL. J Immunol (2001) 166:1690-7. doi:10.4049/jimmunol.166.3.1690.
169. Kedl RM, Rees WA, Hildeman DA, Schaefer B, Mitchell T, Kappler J, et al. T cells compete for access to antigen-bearing antigen-presenting cells. J Exp Med (2000) 192:1105-13. doi:10.1084/jem.192.8.1105.
170. Turula H, Smith CJ, Grey F, Zurbach KA, Snyder CM. Competition between T cells maintains clonal dominance during memory inflation induced by MCMV. Eur J Immunol (2013) 43:1252-63. doi:10.1002/eji.201242940.
171. Brentville VA, Metheringham RL, Gunn B, Durrant LG. High avidity cytotoxic T lymphocytes can be selected into the memory pool but they are exquisitely sensitive to functional impairment. PLoS One (2012) 7:e41112. doi:10.1371/journal.pone.0041112.
172. Vigano S, Bellutti Enders F, Miconnet I, Cellerai C, Savoye AL, Rozot V, et al. Rapid perturbation in viremia levels drives increases in functional avidity of HIV-specific CD8 T cells. PLoS Pathog (2013) 9:e1003423. doi:10.1371/journal.ppat.1003423.
173. Black CM, Armstrong TD, Jaffee EM. Apoptosis-regulated low-avidity cancer-specific CD8(+) T cells can be rescued to eliminate HER2/neu-expressing tumors by costimulatory agonists in tolerized mice. Cancer Immunol Res (2014) 2:307-19. doi:10.1158/2326-6066.CIR-13-0145.
174. Bos R, Marquardt KL, Cheung J, Sherman LA. Functional differences between low-and high-affinity CD8(+) T cells in the tumor environment. Oncoimmunology (2012) 1:1239-47. doi:10.4161/onci.21285.
175. Janicki CN, Jenkinson SR, Williams NA, Morgan DJ. Loss of CTL function among high-avidity tumor-specific CD8+ T cells following tumor infiltration. Cancer Res (2008) 68:2993-3000. doi:10.1158/0008-5472.CAN-07-5008.
176. Weiss VL, Lee TH, Song H, Kouo TS, Black CM, Sgouros G, et al. Trafficking of high avidity HER-2/neu-specific T cells into HER-2/neu-expressing tumors after depletion of effector/memory-like regulatory T cells. PLoS One (2012) 7:e31962. doi:10.1371/journal.pone.0031962.
177. Zhu Z, Singh V, Watkins SK, Bronte V, Shoe JL, Feigenbaum L, et al. High-avidity T cells are preferentially tolerized in the tumor microenvironment. Cancer Res (2013) 73:595-604. doi:10.1158/0008-5472.CAN-12-1123